From the Department of Radiology (T.T., M.Y., A.K.) and Department of Hematology and Medical Oncology (A.H.B.), Mayo Clinic, Scottsdale, Ariz; Department of Radiology, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan (T.T., R.I., S.K.); and Department of Radiology, Mayo Clinic, Rochester, Minn (A.T.F.).
Radiographics. 2020 May-Jun;40(3):709-726. doi: 10.1148/rg.2020190121. Epub 2020 Mar 20.
Relapsing level of prostate-specific antigen (PSA) after initial curative-intent local therapy for organ-confined prostate cancer is often the first sign of recurrence. However, PSA level recurrence does not enable accurate differentiation of locally recurrent tumor from metastatic disease or a combination of both. Metastatic prostate cancer most frequently involves bones and lymph nodes, followed by other organs such as the liver, lung, pleura, adrenal gland, ureter, peritoneum, penis, testis, and meninges. Conventional imaging including CT and bone scintigraphy has long been the standard of care but has limited sensitivity in depicting early local recurrence or metastatic disease. Multiparametric MRI has been shown to be more sensitive in detecting locally recurrent tumor in the prostatectomy bed as well as in situ recurrence in a prostate gland that has been treated with radiation therapy or thermal ablation. In addition, lesions detected with multiparametric MRI may be amenable to targeted biopsy for definitive diagnosis of recurrence. PET/CT or PET/MRI using the U.S. Food and Drug Administration (FDA)-approved tracers carbon 11 choline or fluorine 18 fluciclovine has demonstrated markedly increased sensitivity and specificity for diagnosis of early metastatic disease such as small-volume lymph node metastasis, as have a range of investigational gallium 68 prostate-specific membrane antigen (PSMA) radioactive PET tracers. With recent advances in imaging modalities and techniques, more accurate early detection, localization, and characterization of recurrent prostate cancer have become possible. The authors present a contemporary review of the strengths and limitations of conventional and advanced imaging modalities in evaluation of patients with recurrent prostate cancer and a systematic review of the clinical and imaging features of locally recurrent and metastatic disease.RSNA, 2020See discussion on this article by Barwick and Castellucci.
初始治愈性局部治疗后前列腺特异性抗原 (PSA) 水平复发常常是复发的第一个迹象。然而,PSA 水平的复发并不能准确地区分局部复发性肿瘤与转移性疾病或两者的组合。转移性前列腺癌最常累及骨骼和淋巴结,其次是其他器官,如肝脏、肺、胸膜、肾上腺、输尿管、腹膜、阴茎、睾丸和脑膜。包括 CT 和骨闪烁显像在内的常规影像学检查一直是标准的治疗方法,但在描述局部复发或转移性疾病方面敏感性有限。多参数 MRI 已被证明在检测前列腺切除术床局部复发性肿瘤以及已接受放疗或热消融治疗的前列腺原位复发性肿瘤方面更敏感。此外,多参数 MRI 检测到的病变可能适合进行靶向活检,以明确诊断复发。使用美国食品和药物管理局 (FDA) 批准的示踪剂碳 11 胆碱或氟 18 氟脱氧葡萄糖的正电子发射断层扫描/计算机断层扫描 (PET/CT) 或正电子发射断层扫描/磁共振成像 (PET/MRI) 已证明对诊断早期转移性疾病(如小体积淋巴结转移)具有明显更高的敏感性和特异性,一系列研究用镓 68 前列腺特异性膜抗原 (PSMA) 放射性 PET 示踪剂也具有这种特性。随着成像方式和技术的最新进展,对复发性前列腺癌的早期更准确的检测、定位和特征化成为可能。作者对常规和先进成像方式在评估复发性前列腺癌患者中的优缺点进行了当代综述,并对局部复发性和转移性疾病的临床和影像学特征进行了系统综述。RSNA,2020 年